Clinical outcomes in cancer patients treated with LMWH and DOACs
| Study . | Reference . | Metastatic cancer . | Active therapy . | Recurrent VTE . | Major bleeding . | Mortality . |
|---|---|---|---|---|---|---|
| CLOT | 37 | 455/776 (67%) | 525/776 (78%) | Dalteparin 27/336 (9%) | Dalteparin 19/338 (6%) | Dalteparin 130/336 (39%) |
| Warfarin 53/336 (17%) | Warfarin 12/335 (4%) | Warfarin 136/336 (41%) | ||||
| CATCH | 38 | 492/900 (55%) | 476/900 (53%) | Tinzaparin 31/449 (6.9%) | Tinzaparin 12/449 (2.7%) | Tinzaparin 150/449 (33.4%) |
| Warfarin 45/451 (10%) | Warfarin 11/451 (2.4%) | Warfarin 138/451 (30.6%) | ||||
| RECOVER I and II | 43 | 28/218 (13%) | NR | Dabigatran 4/114 (3.5%) | Dabigatran 4/114 (3.8%) | Dabigatran 16/114 (14%) |
| Warfarin 5/107 (4.7%) | Warfarin 3/107 (3%) | Warfarin 16/107 (15%) | ||||
| EINSTEIN DVT/PE | 44 | Recurrent or metastatic cancer 102/462 (22%) | Chemotherapy 136/462 (29%) | Rivaroxaban 16/354 (5%) | Rivaroxaban 8/354 (2%) | Rivaroxaban 58/354 (16%) |
| VKA 20/301 (7%) | VKA 15/301 (5%) | VKA 53/301 (18%) | ||||
| AMPLIFY | 45 | 33% | NR | Apixaban 3/81 (3.7%) | Apixaban 2/87 (2.3%) | Apixaban 6% |
| Warfarin 5/78 (6.4%) | Warfarin 4/80 (5%) | Warfarin 7.7% |
| Study . | Reference . | Metastatic cancer . | Active therapy . | Recurrent VTE . | Major bleeding . | Mortality . |
|---|---|---|---|---|---|---|
| CLOT | 37 | 455/776 (67%) | 525/776 (78%) | Dalteparin 27/336 (9%) | Dalteparin 19/338 (6%) | Dalteparin 130/336 (39%) |
| Warfarin 53/336 (17%) | Warfarin 12/335 (4%) | Warfarin 136/336 (41%) | ||||
| CATCH | 38 | 492/900 (55%) | 476/900 (53%) | Tinzaparin 31/449 (6.9%) | Tinzaparin 12/449 (2.7%) | Tinzaparin 150/449 (33.4%) |
| Warfarin 45/451 (10%) | Warfarin 11/451 (2.4%) | Warfarin 138/451 (30.6%) | ||||
| RECOVER I and II | 43 | 28/218 (13%) | NR | Dabigatran 4/114 (3.5%) | Dabigatran 4/114 (3.8%) | Dabigatran 16/114 (14%) |
| Warfarin 5/107 (4.7%) | Warfarin 3/107 (3%) | Warfarin 16/107 (15%) | ||||
| EINSTEIN DVT/PE | 44 | Recurrent or metastatic cancer 102/462 (22%) | Chemotherapy 136/462 (29%) | Rivaroxaban 16/354 (5%) | Rivaroxaban 8/354 (2%) | Rivaroxaban 58/354 (16%) |
| VKA 20/301 (7%) | VKA 15/301 (5%) | VKA 53/301 (18%) | ||||
| AMPLIFY | 45 | 33% | NR | Apixaban 3/81 (3.7%) | Apixaban 2/87 (2.3%) | Apixaban 6% |
| Warfarin 5/78 (6.4%) | Warfarin 4/80 (5%) | Warfarin 7.7% |
NR, not reported.